Background: Belimumab, an anti-B-cell activating factor antibody, is approved for the treatment of auto-antibody positive systemic lupus erythematosus with a high degree of disease activity. Anti... Show moreBackground: Belimumab, an anti-B-cell activating factor antibody, is approved for the treatment of auto-antibody positive systemic lupus erythematosus with a high degree of disease activity. Anti-CD20 B cell depletion with rituximab is used in refractory SLE as well, although with variable responses. We hypothesized that incomplete B cell depletion, related to a surge in BAFF levels following rituximab treatment, can cause ongoing disease activity and flares. The Synbiose 1 study primarily focused on immunological effects and shows the preliminary clinical benefit of combined rituximab and belimumab in SLE. The Synbiose 2 study will evaluate the clinical efficacy of combining belimumab with rituximab in patients with severe SLE, allowing the tapering of prednisolone and mycophenolate. Methods: Synbiose 2 is a phase 3, multicenter, randomized, controlled, open-label 2-year clinical trial. Seventy adults with severe SLE including lupus nephritis will be randomized 1:1 to receive either standard of care consisting of prednisolone and mycophenolate as induction and maintenance treatment, or belimumab and rituximab combined with standard of care as induction treatment, followed by prednisolone and belimumab as maintenance treatment. The primary objective is to assess whether combined B cell therapy will lead to a reduction of treatment failure. Secondary endpoints are complete and partial clinical and renal response and the improvement of SLE-specific autoimmune phenomena. Safety endpoints include the incidence of adverse events, with a special interest in infections. Discussion: The Synbiose 2 trial is the first multicenter phase 3 clinical trial investigating combined B cell targeted therapy in SLE, including lupus nephritis. The outcome of this study will provide further evidence for the clinical efficacy of this new treatment strategy in severe SLE. Show less
First, we described a method to quantify NETs which has the potential to monitor autoantigen load in the setting of autoimmune diseases where NETs play a role in its pathophysiology. The use of... Show moreFirst, we described a method to quantify NETs which has the potential to monitor autoantigen load in the setting of autoimmune diseases where NETs play a role in its pathophysiology. The use of confocal microscopy with multiple z-stacks, makes it a sensitive method. We provided a context of how NETs can be quantified in SLE and AAV. We demonstrated that not all NETs are created equally and translation of NET formation to a digital quantification creates a narrow view. We showed higher ex vivo NET formation in AAV patients with active disease compared to AAV patients with an underlying infection supporting that excessive NET formation is an autoimmune phenomenon. Also, we demonstrated that the observed excessive NET formation is independent of ANCAs.In the next part of this thesis, we focused on new treatments in lupus nephritis. Most importantly, the results of the Sybiose study are shown; a phase 2 proof-of-concept study that included 15 patients with severe, refractory SLE treated with rituximab and belimumab. We showed that RTX+BLM has the ability to reduce autoantibodies, thereby indirectly reducing excessive NET formation in SLE, presumably due to the targeting of autoreactive B cells. Further, we observed a clinical response in our patients while tapering immunosuppressive medication. Show less
In this thesis several aspects of SLE were investigated. First, we studied interobserver agreement concerning class III/IV lupus nephritis lesions in a renal biopsy and found that agreement was... Show moreIn this thesis several aspects of SLE were investigated. First, we studied interobserver agreement concerning class III/IV lupus nephritis lesions in a renal biopsy and found that agreement was poor. This seemed, in part, due to inconsistent or ambiguous definitions as provided in the 2004 ISN/RPS classification. This led us to re-evaluate the current classification with an international group of highly experienced nephrologists. Second, we compared and summarized the lupus nephritis management guidelines that were published in 2012. Third, we studied microchimerism in peripheral blood of women with SLE and control subjects. We found that women with SLE have more microchimerism in their peripheral blood than control subjects. Then, we studied microchimerism in the peripheral blood of women with SLE and control subjects during and after pregnancy. We found that only just after delivery did the SLE patients have more chimeric cells in the granulocyte fraction than control subjects. These results suggest that after pregnancy chimeric cells become undetectable in peripheral blood, but possibly remain at other sites, only to re-emerge after un unknown trigger. Finally, we compared sporadic and familial lupus nephritis to find that, although there were clinical differences, no differences in histology or genetic background were apparent. Show less
Systemic lupus erythematosus (SLE) and its immunosuppressive treatment have a great impact on the patient__s life. Previous studies on SLE have focused on the optimisation of diagnosis and... Show moreSystemic lupus erythematosus (SLE) and its immunosuppressive treatment have a great impact on the patient__s life. Previous studies on SLE have focused on the optimisation of diagnosis and treatment. Less attention has been given to the impact of diagnosis and treatment on patients__ well-being. According to Engel__s biopsychosocial model there is a reciprocal and multifactorial relationship between disease characteristics and patients__ well-being and therefore the patient and not the disease should be the centre of focus. This thesis aimed to produce a biopsychosocial perspective on SLE by investigating both medical care and psychological functioning in patients with SLE. The main results show that a selective use of diagnostic procedures and monitoring of serum drug concentrations do not hamper disease outcome and may even reduce treatment burden. However, also low dose immunosuppressive treatment for SLE remains burdensome. This burden is reflected by a lowered HRQoL and lowered sexual functioning. In view of limitations in the extent to which immunosuppressive treatment can be further lowered, patients' illness perceptions may be targeted to enhance psychological functioning. In addition, treatment outcome may benefit from illness perception modification through a beneficial effect of positive (i.e. more adaptive) treatment perceptions on level of treatment adherence. Show less
O'Flynn, J.; Flierman, R.; Pol, P. van der; Rops, A.; Satchell, S.C.; Mathieson, P.W.; ... ; Daha, M.R. 2011
